Tinea Pedis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Tinea Pedis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The tinea pedis treatment market studied was projected to grow with a CAGR of 4.8% over the forecast period. The major factor attributing to the growth of the market is the increase in the prevalence of fungal infections. Mycotic diseases are global in distribution, but maximum cases are recorded from tropical and subtropical countries. As the number of patients increases the market growth also rises. Furthermore, the increasing research and development programs and funding for the same is boosting the market growth. However, lack of awareness of the treatment and stringent approval regulations constraints the market growth.

Key Market TrendsTopical Segment is Dominating the Tinea Pedis Treatment Market

• The major share of the segment is attributed to the increasing number of fungal infections and the advantages of the topical route of administration over oral. These include a low risk of systemic adverse events and drug interactions, low cost, smaller amounts of drug is used, etc.
• According to the Journal of Applied Microbiology and Biochemistry of 2017, globally, 800 million people in the world have suffered from one or other types of fungal diseases.
• The large patient pool and increasing research and development programs and funding are propelling the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

• North America is expected to dominate the overall market, throughout the forecast period. this is mainly due to the factors such as the presence of key players, well-established healthcare infrastructure are some of the key factors accountable for its large share in the market.
• Furthermore, beneficial government initiatives are expected to increase the market growth. In this region the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market.

Competitive Landscape

The Tinea Pedis Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are GlaxoSmithKline, Bausch Health, Glenmark Pharmaceuticals, Bayer AG, Sanofi, Sun Pharma, Teva Pharmaceutical, Celgene.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Companies Mentioned

GlaxoSmithKline
Bausch Health
Glenmark Pharmaceuticals
Bayer AG
Sun Pharma
Sanofi
Teva Pharmaceutical
Celgene

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.